Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).

被引：0
|
作者：
Xu, Jie
Xie, Lu
Guo, Wei
Tang, Xiaodong
Yang, Rongli
Yan, Taiqiang
Liu, Kuisheng
Gu, Jin
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial
    Xu, Bushu
    Pan, Qiuzhong
    Pan, Hua
    Li, Haomiao
    Li, Xianan
    Chen, Jing
    Pang, Danmei
    Zhang, Baoqing
    Weng, Desheng
    Peng, Ruiqing
    Fang, Meiyu
    Zhang, Xing
    ECLINICALMEDICINE, 2023, 64
  • [22] Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.
    Shen, Lin
    Yu, Xianjun
    Lu, Ming
    Zhang, Xing
    Cheng, Ying
    Zhang, Yanqiao
    Li, Zhiping
    Xu, Jianming
    Weng, Desheng
    Wu, Chunjiao
    Ma, Yue
    Cheng, Ke
    Wang, Wenquan
    Gao, Heli
    Li, Yi
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [24] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
  • [25] Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
    Zhang, Xuyu
    Zhou, Feng
    Lu, Tong
    Zhang, Shun
    Wei, Xuedong
    Qiu, Xuefeng
    Xu, Linfeng
    Guo, Hongqian
    Zhuang, Junlong
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [26] A Single-Arm Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel Monotherapy After Standard Therapy for Advanced NSCLC
    Kato, Y.
    Okuma, Y.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S919 - S920
  • [27] Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases: An open-label, single-arm phase II trial
    Zhu, X.
    Tao, H.
    Kong, C.
    Song, X.
    Zhang, N.
    Chen, C.
    Jiang, N.
    Zhao, L.
    Yan, P.
    He, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S881 - S881
  • [28] Original Article Utidelone-based therapy in advanced or metastatic solid tumors after failure of standard therapies: a prospective, multicenter, single-arm trial
    Qiao, Guanglei
    Liu, Zimei
    Ding, Honghua
    Lu, Hongmin
    Lin, Feng
    Shi, Yang
    Zheng, Leizhen
    Wang, Mei
    Chen, Ying
    Deng, Zhoufeng
    Yu, Liping
    Zhang, Yan
    Yuan, Ying
    Lin, Hongjian
    Ma, Lijun
    Zhang, Jianjun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4514 - 4522
  • [29] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
12345